Skip to main content
SpringerLink
Log in

Analyzing the protection scope limit for biosequence patent claims in China

  • Patents
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Though a patent's protection scope should be based on the content of the claims and written description, determining the protection scope of a biosequence patent has always been a controversial issue in practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Li, W. Nat. Biotechnol. 10, 1001–1003 (2014).

    Article  Google Scholar 

  2. China Patent Law, Article 26.4.

  3. Administrative Retrial Judgment No. 86 by China's Supreme People's Court (2016).

  4. China Patent No. 98813338.5, Thermostable glucoamylase (2006).

  5. China's Guidelines for Patent Examination, Part Two, Chapter 10, 9.3.1.1 (2010).

Download references

Author information

Authors and Affiliations

  1. Wei Li is at the Law School of Zhejiang University of Finance and Economics, Hangzhou, China.,

    Wei Li

Authors
  1. Wei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, W. Analyzing the protection scope limit for biosequence patent claims in China. Nat Biotechnol 36, 811–813 (2018). https://doi.org/10.1038/nbt.4234

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.4234

  • Springer Nature America, Inc.

Search

Navigation